| I-06 Amelia Deitchman Tigecycline-Tetracycline Combination Modeling against Pseudomonas aeruginosa: Application of the General Pharmacodynamic Interaction Term in Various Interaction Models Wednesday 10:30-12:00 |
| I-13 Vincent Madelain Modeling viral kinetics predicts a rapid establishment of the cytotoxic immune response targeting distinct infected cell compartments in SIV controller macaques (ANRS SIC study) Wednesday 10:30-12:00 |
| I-17 Ben Margetts Modelling Cytomegalovirus Growth Kinetics in Immunocompromised Children Wednesday 10:30-12:00 |
| I-63 Leire Ruiz Cerdá Modeling of Interferon effector pathway after viral infection Wednesday 10:30-12:00 |
| II-22 Elin Svensson Linking rifampicin exposure to treatment response over 6 months in patients with pulmonary tuberculosis Wednesday 15:10-16:30 |
| II-23 Lénaïg Tanneau Bedaquiline’s exposure-response relationship evaluated with data from the observational study C209 Wednesday 15:10-16:30 |
| II-24 Joel Tarning Population pharmacokinetic properties of piperaquine in falciparum malaria: An individual participant data meta-analysis Wednesday 15:10-16:30 |
| II-33 Eirini Tsotsou Population pharmacokinetics of gentamycin in hospitalized ICU patients Wednesday 15:10-16:30 |
| II-37 Sami Ullah Population pharmacokinetic analysis of intravenous telavancin in healthy subjects undergoing plasma and tissue microdialysis Wednesday 15:10-16:30 |
| II-40 Elodie Valade Population Pharmacokinetic Modeling of Simeprevir – Odalasvir Interaction in Healthy Volunteers Wednesday 15:10-16:30 |
| II-50 Thanaporn Wattanakul Population pharmacokinetics and cardiovascular safety of piperaquine in African patients with uncomplicated malaria Wednesday 15:10-16:30 |
| III-07 Jose Francis Influence of nevirapine and ritonavir/lopinavir based antiretroviral therapy on Lumefantrine exposure in HIV-1 infected patients. Thursday 09:50-11:20 |
| III-13 Silke Gastine Population Pharmacokinetics of Micafungin in critically ill patients - evaluation of a fixed dose regimen Thursday 09:50-11:20 |
| III-15 Parviz Ghahramani Antimicrobial Drug Development Common Practices in PK-PD Model Selection and Common Misconceptions Thursday 09:50-11:20 |
| III-29 Niklas Hartung Quantifying adaptive resistance in bacteria using well-designed dynamic time-kill curve experiments Thursday 09:50-11:20 |
| III-33 Gailing Li Mechanism-Based Modeling In Chronic Heptatis B Thursday 09:50-11:20 |
| III-47 Johannes Kast Antibiotic Efficacy during Spaceflight: Impact of Simulated Microgravity on Killing of S. pneumoniae by Ciprofloxacin Thursday 09:50-11:20 |
| III-48 Tatiana Khariton Human Population PK Model, Dose Selection and Target Attainment Simulations for CF-301 - a Novel Antibacterial Lysin Thursday 09:50-11:20 |
| III-50 Yun Kim A population pharmacokinetic analysis of voriconazole according to CYP2C19 phenotype in healthy subjects Thursday 09:50-11:20 |
| III-54 Franziska Isabelle Kluwe Population pharmacokinetics of unbound voriconazole following two different routes of administration during sequence therapy Thursday 09:50-11:20 |
| III-60 Anders Kristoffersson A Novel Mechanism-Based Pharmacokinetic-Pharmacodynamic Model Describing Ceftazidime-Avibactam (CAZ-AVI) Efficacy Against β-lactamase-Producing Klebsiella pneumoniae and Pseudomonas aeruginosa Isolates Thursday 09:50-11:20 |
| III-66 Donghwan Lee Population pharmacokinetic analysis of meropenem in Korean patients with acute infections Thursday 09:50-11:20 |
| IV-04 Pascal André Population pharmacokinetics of vancomycin delivered from active calcium sulfate bone graft substitute. Thursday 14:45-16:15 |
| IV-08 Eduardo Asín-Prieto An Immune quantitative network aimed for viral hepatitis B Thursday 14:45-16:15 |
| IV-15 Catalina Barceló Modelling body mass index trajectory in HIV-infected individuals Thursday 14:45-16:15 |
| IV-20 Julie Bertrand Joint pharmacogenetic model of tenofovir and emtricitabine and their active intracellular metabolites in HIV Patients Thursday 14:45-16:15 |
| IV-24 Agnieszka Borsuk-De Moor Tigecycline population pharmacokinetics in patients with severe sepsis or septic shock resulting from abdominal surgery Thursday 14:45-16:15 |
| IV-29 Charles Burdet Joint modeling of moxifloxacin pharmacokinetics and fecal microbiota disruption in healthy volunteers Thursday 14:45-16:15 |
| IV-30 Unai Caballero Pharmacokinetic/pharmacodynamic modeling of anidulafungin time-kill curves against Candida considering antifungal resistance Thursday 14:45-16:15 |
| IV-44 Joannellyn Chiu Pre-clinical Population PK Model of CF-301 - a Novel Antibacterial Lysin Thursday 14:45-16:15 |
| IV-53 Miné De Kock Population Pharmacokinetics of Sulfadoxine and Pyrimethamine: A pooled analysis to Inform Optimal Dosing in African Children with Uncomplicated Malaria. Thursday 14:45-16:15 |
| IV-60 Paolo Denti Lopinavir/Ritonavir Super-boosting Overcomes Interactions In Children Treated With Rifampicin: A Model-Based Approach For Non-Inferiority Trials Thursday 14:45-16:15 |
| IV-67 Sulav Duwal Multiscale, mechanistic pipeline to assess the prophylactic efficacy of anti- HIV compounds Thursday 14:45-16:15 |
| IV-68 Lisa Ehmann Is a pooled population pharmacokinetic model predictive of plasma and microdialysate pharmacokinetics of linezolid in obese and non-obese patients? Thursday 14:45-16:15 |
